Minimal Residual Disease Is a Predictor for Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia (CLL) That Is Independent of the Type or Line of Therapy.

摘要: Abstract 540 The depth of remission in CLL correlates with survival a large number trials regardless the therapy used and depletion minimal residual disease (MRD), when reported, is usually associated improved progression free overall survival. However it not clear whether this outcome due to attainment MRD negativity or eradication surrogate for other variables that predict good response. In order address true impact achieving we present data from 137 patients who were treated between 1996 2007, achieved clinical response had bone marrow examined post-therapy assess status including MRD. assessment was performed single laboratory (HMDS, Leeds, UK) using multicolor flow cytometry capable detecting (MRD) level one cell 10000 leukocytes as recently recommended IWCLL Guidelines. Patients followed median duration 3.1 years (range 0.2 - 12.7) after treatment chlorambucil (n=13), fludarabine (n=17), cyclophosphamide (n=58), mitoxantrone and/or rituxumab (n=8), alemtuzumab (n=29), autologous stem transplantation (n=7) various treatments (n=5). Of these, 48 complete (CR), 24 CR incomplete recovery (CRi), 27 nodular partial (nPR) 38 (PR). Altogether 58 individuals (42.3%) negative at end treatment, 28 CR, 20 CRi, 3 nPR 7 PR patients. Results univariate multivariate analyses are summarized below: Age, prior therapies independently correlated significant multi-variate analysis analysed against age, stage, therapy, cytopenia. One most striking findings having their first treatment. series line (21 following FC, 1 FCR, SCT) an MRD-negative 34 MRD-positive. With follow-up months 7-153) 5 year PFS 89% (95% CI 55-97%) compared 0% positive patient conclusion, demonstrate independent predictor even variety different approaches considered therapy.. This strongest evidence yet appropriate aim fit enough such approach. Furthermore achieve have 95% suggesting optimal time attempt therapy. Disclosures: Hillmen: Roche Pharmaceuticals: Consultancy, Honoraria, Membership on entity9s Board Directors advisory committees, Research Funding; GlaxoSmithKline: committees.